Q1 2023 Results

Company overview Innovation: Pipeline overview Financial review Financial performance Conclusions Our pipeline projects at a glance Innovative medicines Solid Tumors Hematology Immunology Neuroscience Cardiovascular Others Ophthalmology Respiratory & Allergy Global Health Biosimilars¹ Appendix Innovation: Clinical trials References Abbreviations Phase 1/2 Phase 3 Registration Total 81 46 7 134 15 15 2 32 18 8 0 26 20 10 4 34 5 5 0 10 17 6743 62 1 13 0 19 1 0 5 0 0 3 10 1 0 11 n/a 2 0 2 Total 81 48 7 136 1. Selected disclosed, internal projects. Biosimilar pre-Phase 3 are not disclosed. 33 Investor Relations | Q1 2023 Results INNOVATION 1 NOVARTIS | Reimagining Medicine

View entire presentation